Evidence map›Paper›PMID 30653566›Full record

ArticlePloS one2019

HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong's largest independent pathology laboratory.

Lingbo Jiang, Xinxin Tian, Dezhi Peng, Liran Zhang, Fengxiang Xie, Chunrui Bi, Rui Wang, Jiajia Wang, Debo Qi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lingbo JiangDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Xinxin TianDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Dezhi PengDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Liran ZhangDepartment of Pathology, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Fengxiang XieDepartment of Pathology, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Chunrui BiDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Rui WangDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Jiajia WangDepartment of Laboratory Medicine, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.
Debo QiDepartment of Pathology, Jinan KingMed Diagnostics, Jinan, Shandong Province, China.ORCID 0000-0002-7956-5789
Kingmed Diagnostics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData regarding human papillomavirus (HPV) prevalence and genotype distribution are limited in Shandong Province, China. Therefore, we investigated the recent HPV prevalence and genotype distribution among females in Shandong and aimed to provide comprehensive data to guide HPV-based cervical cancer screening and HPV vaccination for this population of Chinese women.

methodsHPV testing results of 94,489 females were retrospectively reviewed and extracted from the database of Jinan KingMed Diagnostics, the largest independent pathology laboratory in Shandong Province, China. HPV was detected by a HPV genotyping panel from January 2011 to June 2017. The overall prevalence, age-specific prevalence, and genotype distribution were analyzed.

resultsA total of 26,839 cases (28.4%) were HPV-positive, with 4.3% positive for low- or undetermined-risk HPV (lr-/urHPV)-only, 18.1% positive for high-risk HPV (hrHPV)-only, and 6.1% positive for mixed lr-/urHPV and hrHPV infections. Single HPV infections accounted for 62.8%, while the rest were multiple HPV infections of two or more genotypes. HPV16 (5.8%), HPV52 (5.1%), HPV58 (3.5%), HPV51 (2.6%), and HPV56 (2.3%) were the five most common hrHPV genotypes; while HPV81 (2.8%), HPV53 (2.8%), and HPV6 (2.3%) were the three most common lr-/urHPV genotypes. HPV18 (1.7%) was only the ninth most common hrHPV genotype. HPV16 but not HPV52 was more common in single infections than in multiple infections. The distribution of both mixed lr-/urHPV and hrHPV as well as overall HPV infections demonstrated a bimodal pattern across age groups, of which the first peak appeared in the younger group and the second peak was found in older women. A similar age-specific distribution was observed in multiple infections of three or more subtypes as well. Moreover, the proportion of mixed lr-/urHPV and hrHPV infection significantly increased, while those of lr-/urHPV-only and hrHPV-only infections declined as the number of co-infections increased during the study period.

conclusionThis large daily clinical practice report shows that HPV prevalence and genotype distribution are different in this population, who had limited cervical cancer screening service, compared to those in developed countries. Therefore, different strategies should be developed for HPV-based cervical cancer screening and vaccine-based HPV prevention in Shandong Province.

Indexed as

AdultAgedChinaFemaleGenotypeHumansMass ScreeningMiddle AgedPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPrevalenceRetrospective StudiesUterine Cervical NeoplasmsPapillomavirus Vaccines

Identifiers

PMID30653566
PMCPMC6336302
OpenAlexW2909508198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.